Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons - Top-Institutions - MDSpire

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

  • By

  • Naseema Gangat

  • Ayalew Tefferi

  • May 7, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloproliferative Neoplasms

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloproliferative Neoplasms

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Myeloproliferative Neoplasms

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloproliferative Neoplasms

  • #5

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, TX

    Key Differentiators

    • Hematology
    • Myeloproliferative Neoplasms

Original Source(s)

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons

  • by Naseema Gangat, Ayalew Tefferi

  • May 7, 2025

Related Content

Comprehensive Spectral Flow Cytometry Approach for Concurrent Analysis of Hematopoietic Stem, Progenitor, and Mature Cell Lineages in Murine Bone Marrow

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise

Fistulizing Crohn's disease

Luca Stocchi, M.D., a colorectal surgeon at Mayo Clinic in Florida, presents a surgical case involving a 53-year-old male with long-standing, fistulizing Crohn's disease. The patient had a prior open ileocolic resection and subsequently developed progressive weight loss and anemia.

  • January 5, 2026

  • 1 min